Piramal Pharma Solutions
Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Pharma, providing end-to-end drug development and manufacturing services to pharmaceutical and biotech clients worldwide.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Piramal Pharma Solutions (PPS) is the contract development and manufacturing organization (CDMO) business of Piramal Pharma Limited, part of the Indian diversified Piramal Group. It serves pharmaceutical, biotech and life-sciences companies as an outsourcing partner across the drug lifecycle, from early discovery and development through commercial manufacturing. PPS operates an integrated network of development and manufacturing sites across India, North America, the United Kingdom and Europe, offering services such as API (active pharmaceutical ingredient) development and manufacturing, formulation development, clinical trial supply, and commercial-scale finished-dosage manufacturing, including sterile injectables, oral solids and highly potent compounds. Its customer base spans global pharma majors, specialty pharma and emerging biotech companies. As part of Piramal Pharma, PPS sits alongside the group's other pharma businesses, including its complex hospital generics and consumer healthcare operations. The CDMO segment is a core growth pillar for Piramal Pharma, which was carved out of Piramal Enterprises and separately listed in India. PPS positions itself as a flexible, quality-focused outsourcing partner with multi-site, multi-geography capabilities and a track record in handling complex chemistries and potent compounds. The brand is best understood as a B2B services platform rather than a consumer product brand: its identity rests on manufacturing excellence, regulatory compliance (US FDA, EMA and other agencies), and long-term supply relationships with innovator and generic drug companies.
History
Piramal Pharma Solutions emerged from the Piramal Group's expansion into pharmaceutical services. The Piramal Group, founded by Ajay Piramal, built its pharma presence through acquisitions and organic growth, notably acquiring the Indian formulations business of Nicholas Piramal and later the healthcare solutions business of Abbott's Indian operations. The group's contract manufacturing and custom synthesis capabilities were consolidated under the Piramal Pharma umbrella. As global pharma companies increasingly outsourced development and manufacturing, Piramal expanded its CDMO footprint through acquisitions and site investments in North America, the UK and Europe, adding capabilities in antibody-drug conjugates, sterile manufacturing and highly potent APIs. These moves positioned Piramal Pharma Solutions among India-headquartered CDMOs with a global manufacturing network. In 2020, Piramal Enterprises demerged its pharmaceutical business into Piramal Pharma Limited, creating a dedicated pharma entity. Piramal Pharma subsequently raised growth capital from The Carlyle Group and listed on Indian stock exchanges in 2022, giving Piramal Pharma Solutions a separately capitalized parent focused on CDMO, complex hospital generics and consumer healthcare. PPS has continued to invest in capacity expansion and capability building, including sterile fill-finish, peptide and oligonucleotide capabilities, and ADC manufacturing, responding to demand from innovator biotech clients. Its brand identity centers on being a reliable, quality-driven outsourcing partner with integrated development-to-commercial offerings.
- 2022
Piramal Pharma lists on Indian stock exchanges
- 2020
Piramal Enterprises demerges its pharmaceutical business into Piramal Pharma Limited
Products and positioning
B2B contract development and manufacturing partner for global pharmaceutical and biotech companies, emphasizing complex chemistry, multi-site capacity and regulatory compliance.
API development and manufacturing
Formulation development
Clinical trial supply
Commercial manufacturing
Recent events
Piramal Pharma completes acquisition of controlling stake in Yapan Bio[1]
Reported:
Piramal Pharma Ltd. completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited for an aggregate cash consideration of ₹76 crore ($7.95M USD), bringing its ownership to 74% and making Yapan Bio a subsidiary.
Piramal Pharma acquires Hemmo Pharmaceuticals[2]
Reported:
Piramal Pharma Limited's Contract Development and Manufacturing Organization, Piramal Pharma Solutions, fully acquired Hemmo Pharmaceuticals for Rs 775 crore.
Piramal Pharma Solutions announces agreement to acquire Sellersville facility[3]
Reported:
Piramal Pharma Solutions announced an agreement to acquire G&W Laboratories' solid oral dosage drug product manufacturing facility in Sellersville, Pennsylvania. Closing is subject to customary pre-closing conditions.
Piramal Pharma Solutions to partner with BerGenBio on bemcentinib development[4]
Reported:
Piramal Pharma Solutions announced that it will partner with Norway-based BerGenBio ASA on development of bemcentinib for elderly patients with relapsed Acute Myeloid Leukemia. The announced program includes development and manufacturing activities across India, North America, and Europe.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/piramal-pharma-solutions · Editorial policy · How profiles are compiled